Current Advances in Chimeric Antigen Receptor Technology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 50168
Special Issue Editors
Interests: immunotherapy; gene and cell therapy; cytokine signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
In recent years, there has been a significant advancement in the area of cellular immunotherapy, best exemplified by the remarkable success of the FDA-approved autologous chimeric antigen receptor (CAR) T cell therapy cells in patients with hematological malignancies. The application of CAR has been rapidly applied to other cells, such as natural killer (NK) cells, relieving drawbacks associated with the high cost and toxicity of CAR-T therapy. Currently, accelerated by synthetic biology, the design of CAR constructs is fast developing for specific recognition of cancerous cells and optimal antitumor response. These efforts will provide insight into the generation of safe and robust cytotoxic cells applicable to both blood and solid tumors as deliverable drugs.
In this Special Issue, we welcome authors to submit original research articles and reviews, more precisely:
- Original research articles that provide preclinical and clinical evidence for potent CAR-mediated immunotherapies;
- Reviews on the advances of CAR technology on each generation, and obstacles to address in future.
Prof. Seung-Hwan Lee
Dr. Scott McComb
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chimeric antigen receptors (CARs)
- CAR-T cell therapy
- CAR-NK cell therapy
- natural killer (NK) cells
- adoptive cell therapy
- cancer immunotherapy
- cancers
- cytotoxicity
- cytokine production
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.